PDF(Pubmed)
Abstract：
The aim of the present study was to evaluate the diagnostic and prognostic significance of the long non-coding RNA (lncRNA) endoplasmic reticulum membrane protein complex subunit 3 antisense RNA 1 (EMC3-AS1) in liver cancer, and its impact on the proliferative and invasive capabilities of liver cancer cells. EMC3-AS1 expression in liver cancer was assessed using data from The Cancer Genome Atlas and three Gene Expression Omnibus datasets, and validated in clinical liver cancer samples using reverse transcription-quantitative PCR. The prognostic and diagnostic potentials of this lncRNA were evaluated using Kaplan-Meier and receiver operating characteristic analyses, respectively. The infiltration of immune cells and differential expression of immune checkpoints (ICs) between high- and low-EMC3-AS1 expression groups were investigated. Therapeutic correlation analyses were also undertaken to assess the impact of EMC3-AS1 in the treatment of liver cancer. In addition, in vitro experiments were conducted using small interfering RNA to knock down the expression of EMC3-AS1 in HepG2, Sk-Hep-1 and Huh-7 cells, and evaluate the effect on cell proliferation, colony formation and migration. The results revealed a significant upregulation of EMC3-AS1 expression in liver cancer tissues compared with that in adjacent normal tissues, which was associated with an unfavorable prognosis and demonstrated diagnostic effectiveness for patients with liver cancer. Furthermore, patients with high EMC3-AS1 expression exhibited increased levels of IC markers in comparison with those with low EMC3-AS1 expression. In addition, EMC3-AS1 was indicated to have clinical significance in the prediction of the response to immunotherapy and chemotherapy. Notably, the in vitro experiments demonstrated that the knockdown of EMC3-AS1 significantly hindered cell proliferation, colony formation and migration. Consequently, it was concluded that EMC3-AS1 is upregulated in liver cancer and serves as a prognostic indicator for unfavorable outcomes in patients with liver cancer. Additionally, targeting EMC3-AS1 through knockdown interventions showed potential in mitigating the ability of liver cancer cells to proliferate and migrate, which highlights its dual role as a biomarker and therapeutic target for liver cancer.
摘要：
本研究的目的是评估长链非编码RNA（lncRNA）内质网膜蛋白复合物亚基3反义RNA1（EMC3-AS1）在肝癌中的诊断和预后意义，及其对肝癌细胞增殖和侵袭能力的影响。使用来自癌症基因组图谱和三个基因表达综合数据集的数据评估肝癌中的EMC3-AS1表达，并在临床肝癌样本中使用逆转录-定量PCR进行验证。使用Kaplan-Meier和接受者操作特征分析评估了该lncRNA的预后和诊断潜力，分别。研究了高和低EMC3-AS1表达组之间的免疫细胞浸润和免疫检查点（IC）的差异表达。还进行了治疗相关性分析以评估EMC3-AS1在肝癌治疗中的影响。此外,在体外实验中，使用小干扰RNA敲低EMC3-AS1在HepG2，Sk-Hep-1和Huh-7细胞中的表达，并评估对细胞增殖的影响，菌落的形成和迁移。结果表明，与癌旁正常组织相比，肝癌组织中EMC3-AS1的表达明显上调，这与不良预后相关，并证明了对肝癌患者的诊断有效性。此外，与EMC3-AS1低表达患者相比,EMC3-AS1高表达患者的IC标志物水平升高.此外,表明EMC3-AS1在预测对免疫疗法和化学疗法的反应中具有临床意义。值得注意的是,体外实验表明，EMC3-AS1的敲低显著阻碍了细胞增殖，菌落的形成和迁移。因此,结论EMC3-AS1在肝癌中上调,可作为肝癌患者不良结局的预后指标.此外,靶向EMC3-AS1通过敲低干预显示在减轻肝癌细胞增殖和迁移能力的潜力，这突出了它作为肝癌的生物标志物和治疗靶点的双重作用。
